Business Wire

CA-MFA

Share
MFA Delivers New Tools for Enterprises to Simplify Their Private Network Deployments

MFA, the industry Alliance supporting private network adoption, today announced that it is launching a new resource center on its website for enterprises to gain access to tools that will aid their 3GPP-based private network deployments and to highlight private networks globally. Enterprises can access these tools to simplify their own private network deployments and to learn about available spectrum options in their region.

“The connectivity requirements of enterprises are becoming more complex, with thousands of devices on a network conducting business-critical applications,” said Mazen Chmaytelli, president, MFA. “MFA is a leading industry resource for enterprises looking to understand the benefits and opportunities of 3GPP-based private networks for their business. Our mission is to make it as easy as possible for enterprises to deploy their own private network in any spectrum, and we are providing the tools and resources to help them facilitate that and achieve their digitalization goals.”

As part of its new private networks resource center, MFA is launching a private network tracker in partnership with industry analyst firm, Mobile Experts. The tracker provides insight into the state of private networks across various industry verticals and enterprises as well as regions where private networks are gaining ground.

“As of the end of June 2022, Mobile Experts estimates that more than 2,800 private LTE and 5G networks have been cumulatively deployed,” said Kyung Mun, principal analyst, Mobile Experts. “We also forecast that the private cellular equipment market will grow 12-15% this year to $1.9B and continue to ramp as the industrial device ecosystem scales. We also see that additional regulators are taking their cue from early actions in Germany, Japan, USA and the UK to make available dedicated private 5G spectrum. MFA will be providing ongoing updates on private network deployments globally so enterprises can learn about trends and best practices.”

New monthly newsletter
Enterprises are encouraged to subscribe to MFA’s new newsletter that will feature a monthly update on private networks deployed globally in a variety of industries, as well as feature new white papers, case studies, and resources. Subscribe at www.mfa-tech.org/newsletter.

Uni5G Technology Blueprints available for enterprises
MFA has also made its Uni5G™ Technology Blueprints publicly available for any enterprise to download. The blueprints leverage 3GPP 5G standards to define profiling and classification requirements for private networks. Enterprises can use the blueprints as a tool with their vendor of choice to let them know which select features their devices need to implement. The initial set of blueprints is based on 3GPP Release 15, and the next set of blueprints based on Release 16 and beyond are under development.

Meet us at Hannover Messe USA
MFA will be presenting at Hannover Messe USA in the Solutions Theater located in Building 1, Level 3.

  • Monday, Sept. 12, 10:30-11:00AM: Practical Tools to Simplify Your Private Network Deployment by Mazen Chmaytelli, MFA President
  • Friday, Sept. 16, 11:15-11:45AM: Deploying a Private 5G Network Doesn’t have to be Rocket Science by Asimakis Kokkos, MFA Technical Specification Group Chair

MFA representatives will also showcase technology solutions and resources in Booth #134661. To schedule a meeting with MFA’s private network experts, contact press@mfa-tech.org.

Resources:

About MFA
MFA is an industry Alliance supporting private network adoption. We provide resources that simplify the path to optimized, reliable and secure private networks in locally licensed, shared, or unlicensed spectrum. MFA enables the ecosystem with its free Uni5G™ Technology Blueprints and its unique global PLMN-ID program. Uni5G, based on 3GPP specifications, identifies the key 5G features needed for enterprises to successfully deploy their own private network. MFA is a 3GPP Market Representation Partner. Learn more at www.mfa-tech.org.

Become an MFA member
Join MFA as a contributor or an adopter member to participate in working groups, receive complimentary access to MFA’s Private Network Identifier packages, and to augment your company’s marketing activities. Learn more at Join | MFA (mfa-tech.org).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005526/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release

The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow

DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release

MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa

VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release

Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye